Evidence map›Paper›PMID 38896345›Full record

ArticleActa neuropathologica2024

Annexin A11 aggregation in FTLD-TDP type C and related neurodegenerative disease proteinopathies.

John L Robinson, EunRan Suh, Yan Xu, Howard I Hurtig, Lauren Elman, Corey T McMillan, David J Irwin, Sílvia Porta, Vivianna M Van Deerlin, Edward B Lee

Abstract read
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Development of [Nature communications · 2025
    Article
  20. Celebrating neuropathology's contributions to Alzheimer's Disease Research Centers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

John L RobinsonCenter for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute On Aging, Perelman School of Medicine, University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA.
EunRan Suh *Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute On Aging, Perelman School of Medicine, University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA.
Yan XuCenter for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute On Aging, Perelman School of Medicine, University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA.
Howard I HurtigDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Lauren ElmanDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Corey T McMillanDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
David J IrwinDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sílvia PortaCenter for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute On Aging, Perelman School of Medicine, University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA. silviap@pennmedicine.upenn.edu.
Vivianna M Van DeerlinCenter for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute On Aging, Perelman School of Medicine, University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA. vivianna@upenn.edu.
Edward B LeeCenter for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute On Aging, Perelman School of Medicine, University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA. edward.lee@pennmedicine.upenn.edu.ORCID 0000-0002-4589-1180

Funding

Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Understanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI David John Irwin, Corey T McMillan · 2020 to 2026
$18.8M
Project IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI CHEN-PLOTKIN, ALICE S · 2019 to 2023
$18.1M
Biochemical and molecular heterogeneity of human TDP-43 proteinopathies in age-related dementiasR01AG075276 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Silvia Porta Antolinez · 2022 to 2026
$3.0M
Loss of VCP Function in Frontotemporal Lobar DegenerationRF1AG065341 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, EDWARD BYUNG-HA · 2022 to 2022
$2.4M
Loss of VCP Function in Frontotemporal Lobar DegenerationR01AG065341 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Edward Byung-Ha Lee · 2025 to 2026
$1.5M
NIA NIH HHS P01 AG066597NIA NIH HHS P01AG066597NIA NIH HHS P30 AG072979NIA NIH HHS P30AG072979NIA NIH HHS R01 AG065341NIA NIH HHS R01 AG075276NIA NIH HHS RF1 AG065341NIA NIH HHS RF1AG065341NIA NIH HHS U19 AG062418NIA NIH HHS U19AG062418
6 · The paper itself

Abstract

TAR DNA-binding protein 43 (TDP-43) is an RNA binding protein found within ribonucleoprotein granules tethered to lysosomes via annexin A11. TDP-43 protein forms inclusions in many neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) and limbic predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC). Annexin A11 is also known to form aggregates in ALS cases with pathogenic variants in ANXA11. Annexin A11 aggregation has not been described in sporadic ALS, FTLD-TDP or LATE-NC cases. To explore the relationship between TDP-43 and annexin A11, genetic analysis of 822 autopsy cases was performed to identify rare ANXA11 variants. In addition, an immunohistochemical study of 368 autopsy cases was performed to identify annexin A11 aggregates. Insoluble annexin A11 aggregates which colocalize with TDP-43 inclusions were present in all FTLD-TDP Type C cases. Annexin A11 inclusions were also seen in a small proportion (3-6%) of sporadic and genetic forms of FTLD-TDP types A and B, ALS, and LATE-NC. In addition, we confirm the comingling of annexin A11 and TDP-43 aggregates in an ALS case with the pathogenic ANXA11 p.G38R variant. Finally, we found abundant annexin A11 inclusions as the primary pathologic finding in a case of progressive supranuclear palsy-like frontotemporal dementia with prominent striatal vacuolization due to a novel variant, ANXA11 p.P75S. By immunoblot, FTLD-TDP with annexinopathy and ANXA11 variant cases show accumulation of insoluble ANXA11 including a truncated fragment. These results indicate that annexin A11 forms a diverse and heterogeneous range of aggregates in both sporadic and genetic forms of TDP-43 proteinopathies. In addition, the finding of a primary vacuolar annexinopathy due to ANXA11 p.P75S suggests that annexin A11 aggregation is sufficient to cause neurodegeneration.

Indexed as

AnnexinsDNA-Binding ProteinsFrontotemporal Lobar DegenerationAgedAged, 80 and overAmyotrophic Lateral SclerosisBrainFemaleHumansInclusion BodiesMaleMiddle AgedNeurodegenerative DiseasesProtein Aggregation, PathologicalTDP-43 ProteinopathiesAnnexinsDNA-Binding ProteinsTARDBP protein, humanALSAnnexin A11FTLD–TDPNeurodegenerative diseaseTDP-43

Identifiers

PMID38896345
PMCPMC11186923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.